GlobeNewswire

Bermuda Principles event merges science and business

Dela

HAMILTON, Bermuda, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Scientists and researchers from around the world are gathering in Bermuda this week for the second edition of a conference exploring the field of genetic research.

Premier the Hon David Burt will officially open "Bermuda Principles: Impact on Splicing" Wednesday evening at the Fairmont Southampton. The conference, which runs through Saturday, has registered 50 delegates, along with an impressive roster of 36 speakers and panellists from 11 countries, including Australia, Denmark, Switzerland and South Africa.  Among the attendees are prominent geneticists, scientists, professors, researchers, PhD students working in international labs, biotech representatives and investors.

"I am elated to see the growth of the conference since last year's event," said Bermudian Dr. Carika Weldon, a biomedical researcher with her own lab at De Montfort University, UK, who conceived of the event and launched it last February. "My main aim has been to promote the Bermuda Principles document that was created at a conference that took place here back in 1996, and it's awesome to realise that thanks to the work we've done, more Bermudians, including our MPs, know about this now. It's an important legacy, and we should all be proud of the role Bermuda has played in genetics history."

In 1996, a scientific milestone occurred in Bermuda, after US and UK scientists met on the island to negotiate the completion of the Human Genome Project. In a landmark agreement, they decided gene sequences developed by numerous private labs would be made publicly available worldwide to advance scientific research. The agreement, called "The Bermuda Principles," contributed to the pace and reach of scientific research that followed.

This year's conference pays tribute to that history, while forging forward with a contemporary agenda of sessions dedicated to topics ranging from bioinformatics, regulation, technologies, therapeutics, gene splicing and disease, and commercialisation of university research. Speakers include keynote Adrian Krainer, Professor at Cold Spring Harbor Laboratory, New York; Jean Beggs, Fellow of the Royal Society and Professor, Edinburgh; Daniel Larson, of the Center for Cancer Research, Maryland; Franco Pagani, of the International Centre for Genetic Engineering and Biotechnology in Trieste, Italy; and Robin Reed, Professor of Cell Biology, Harvard Medical School.

One of the conference highlights will focus on how to commercialise scientific ideas, leveraging investment to turn them into viable businesses.

"As a researcher at a university, I had to quickly realise that what I was doing today could become a business venture tomorrow," said Weldon, who is also creating a foundation to promote science in the Bermuda community. "I have had to get my own head around commercialisation. In academia, we're taught to do experiments and publish, but sometimes that prevents you from turning an idea into a profitable venture. That's why I wanted to include this topic in the conference."

The closing session will feature the BDA's consultant for Emerging Technologies John Narraway and others discussing the island's attraction to biotech investors as a blue-chip international finance centre. It's one of numerous public-engagement events linking science to education, healthcare and business that will see conference participation by students, teachers, and medical and corporate professionals.

"Bermuda has long been the domicile for many established and well-known biotech companies," noted Narraway. "We see a conference like this as an opportunity to build a new ecosystem for early-stage biotech and life-science ventures. The BDA is participating in the event as a way to connect with these researchers and show the value the island can bring to those looking to transform their research into a commercial opportunity and licensable product."

Thursday night will feature a Bermuda Youth Parliament debate on the research use of immortal HeLa cells derived from a cancer patient. The event, to be live-streamed on Facebook, Twitter and Instagram, will be opened by Dr. Daniel Ford, Professor of Medicine at the Johns Hopkins University School of Medicine. Bermuda MPs have been invited to attend and winning students will receive smart phones courtesy of Digicel.

On Friday, local high-schoolers will carry out a genetic-engineering experiment using kits provided by Amino Labs in which colourful jellyfish DNA will be added to bacteria.

Saturday afternoon will see science teachers from local schools join doctors and other professionals for a panel discussion on integrating research into healthcare and education curricula.

The leading partner of the conference is Bank of Bermuda Foundation. Sponsors include: Bermuda Business Development Agency (BDA), Bermuda Technology Initiative, Bermuda Tourism Authority (BTA), De Montfort University, New England BioLabs, RNA Society, Island Press and Amino Labs.

MEDIA CONTACT:

Rosemary Jones
Head of Communications & Marketing
rosemary@bda.bm
441 278-6558
441 337-4696

CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business here smooth and beneficial.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0493acf0-aeec-4be0-88a2-3e42938c6112




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bermuda Business Development Agency (BDA) via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum